Page 1

Dexcom® Dexcom Reports Second Quarter 2021 Financial Results July 29 , 2021 SAN DIEGO -- ( BUSINESS WIRE ) -- Jul . 29 , 2021-- DexCom . Inc. ( Nasdaq : DXCM ) today reported its financial results as of and for the quarter ended June 30 , 2021 . Second Quarter 2021 Financial Highlights : • Revenue grew 32 % versus the same quarter of the prior year to $ 595.1 million • U.S. revenue growth of 26 % and international revenue growth of 58 % • GAAP operating income of $ 101.0 million or 17.0 % of revenue , an increase of 200 basis points compared to the second quarter of 2020. Non - GAAP operating income * of $ 101.5 million or 17.1 % of revenue , an increase of 10 basis points over the same quarter of the prior year Strategic Highlights : • In June , reported compelling data demonstrating the efficacy of Dexcom's current and future CGM platforms : o The Lancet published results from the ALERTT1 randomized controlled trial demonstrating superior clinical outcomes for users of Dexcom G6 real - time CGM compared to intermittently scanned CGM.¹ o The Journal of the American Medical Association ( JAMA ) published results from the MOBILE randomized controlled trial , demonstrating strong clinical advantages of Dexcom CGM versus the current standard of care in adults with poorly controlled Type 2 diabetes on basal insulin without prandial insulin.² o Dexcom presented strong preliminary data for its next - generation G7 CGM System at the International Conference on Advanced Technologies & Treatments for Diabetes ( ATTD ) conference . • Advanced access to Dexcom CGM for people with diabetes in several regions , including British Columbia as the first Canadian province to establish coverage for Dexcom G6 CGM systems for people with Type 1 diabetes and Type 2 diabetes on intensive insulin therapy . • After the conclusion of the quarter , announced FDA clearance of Dexcom's real - time API , furthering the company's emphasis on interoperable solutions for tailored experiences with Dexcom CGM . 1 Visser et al . , " Comparing real - time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes ( ALERTT1 ) : a 6 - month , prospective , multicentre , randomised controlled trial , " Lancet , June 2 , 2021. ( https://doi.org/10.1016/S0140-6736(21)00789-3 ) . Study results included statistically significant differences in time in range , HbA1c , time spent in severe hypoglycemia , Hypoglycemia Fear , and severe hypoglycemia events . 2 Martens et al . , " Effect of Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Treated with Basal Insulin : A Randomized Clinical Trial , " JAMA , June 2 , 2021. ( doi : 10.1001 / jama.2021.7444 ) . " Dexcom's second quarter performance was characterized by strong financial results and the continued advancement of our key strategic initiatives , " said Kevin Sayer , Dexcom's chairman , president and CEO . " Our underlying momentum led to the increased revenue and margin guidance that we reported today and leaves us increasingly excited as we head into the second half of 2021. " 2021 Annual Guidance Based on the strong second quarter results , Dexcom is increasing its guidance for fiscal year 2021 revenue , Non - GAAP gross profit margin , Non - GAAP operating margin , and Adjusted EBITDA margin to the following levels : • Revenue of approximately $ 2.35 - 2.40 billion ( 22-25 % growth ) • Non - GAAP Gross Profit Margin of approximately 67 % • Non - GAAP Operating Margin of approximately 14 % ● Adjusted EBITDA Margin of approximately 24 % Second Quarter 2021 Financial Results Revenue : In the second quarter of 2021 , worldwide revenue grew 32 % to $ 595.1 million , up from $ 451.8 million in the second quarter of 2020. Volume growth in conjunction with strong new customer additions continues to be the primary driver of revenue growth as awareness of real - time CGM increases . Gross Profit : GAAP gross profit totaled $ 417.1 million or 70.1 % of revenue for the second quarter of 2021 , compared to $ 284.1 million or 62.9 % of revenue in the second quarter of 2020 . Non - GAAP gross profit * totaled $ 417.1 million or 70.1 % of revenue for the second quarter of 2020 , compared to $ 289.7 million or 64.1 % of revenue in the second quarter of 2020. The second quarter 2020 non - GAAP amount excludes $ 5.6 million of incremental labor costs incurred as a result of the COVID - 19 outbreak . Operating Income : GAAP operating income for the second quarter of 2021 was $ 101.0 million , compared to GAAP operating income of $ 67.8 million